CodeMap® 
150 North Wacker Drive
Suite 1870
Chicago, IL 60606
847-381-5465 Phone
847-381-4606 Fax
customerservice@codemap.com
      


User Information

Create New Account

Lost Password

Username:
Password:


Quick Links

LCDs and LCAs
by Contractor

PLA Codes

Laboratory Fee Schedule

2022
2021

Physician Fee Schedule

2022
2021

OPPS Fee Schedule

2022-October
2022-July

ASC Fee Schedule

2022-October
2022-July

APC Codes

2022-October
2022-July

DRG Codes

2022
2021

ASP Drug Pricing Files

October 2022
July 2022


CMS Transmittals



CodeMap® LCD-L36276

 

Printer Friendly Version

L36276
LCD for Erythropoiesis Stimulating Agents (L36276)
See related Articles:
A57628-Billing and Coding: Erythropoiesis Stimulating Agents

Contractor Information

Contractor Name: First Coast Service Options, Inc. - Full list of policies of this Medicare Contractor

Contractor Number: 09101

Contractor Type: MAC A

LCD Information

LCD ID Number: L36276 Status: A-Approved

LCD Title: Erythropoiesis Stimulating Agents

Geographic Jurisdiction: Florida Other Jurisdictions

Original Determination Effective Date: 10/01/2015

Original Determination Ending Date:

Revision Effective Date: 09/07/2021

Revision End Date:

CMS National Coverage Policy:

This LCD supplements but does not replace, modify or supersede existing Medicare applicable National Coverage Determinations (NCDs) or payment policy rules and regulations for Erythropoiesis Stimulating Agents. Federal statute and subsequent Medicare regulations regarding provision and payment for medical services are lengthy. They are not repeated in this LCD. Neither Medicare payment policy rules nor this LCD replace, modify or supersede applicable state statutes regarding medical practice or other health practice professions acts, definitions and/or scopes of practice. All providers who report services for Medicare payment must fully understand and follow all existing laws, regulations and rules for Medicare payment for Erythropoiesis Stimulating Agents and must properly submit only valid claims for them. Please review and understand them and apply the medical necessity provisions in the policy within the context of the manual rules. Relevant CMS manual instructions and policies may be found in the following Internet-Only Manuals (IOMs) published on the CMS Web site. 

Internet Only Manual (IOM) Citations:

  • CMS IOM Publication 100-02, Medicare Benefit Policy Manual,
    • Chapter 6, Sections 10.2, Other Circumstances in Which Payment Cannot Be Made Under Part A and Section 30 Drugs and Biologicals
    • Chapter 11, Section 20.3 Drugs and Biologicals, and 100.6 Applicability of Specific ESRD PPS Policies to AKI Dialysis
    • Chapter 15, Section 50.5.2 Erythropoietin (EPO)
  • CMS IOM Publication 100-03, Medicare National Coverage Determinations (NCD) Manual,
    • Chapter 1, Part 2, Section 110.21 Erythropoiesis Stimulating Agents (ESAs) in Cancer and Related Neoplastic Condition
  • CMS IOM Publication 100-04, Medicare Claims Processing Manual,
    • Chapter 6, Section 20.2 Services Excluded from Part A PPS payment
    • Chapter 7, Section 100 Epoetin (EPO)
    • Chapter 8, Section 30 Publication of the Prospective Payment System (PPS) Base Rate, Section 50 In-Facility Dialysis Bill Processing Procedures, Section 70 Payment for Home Dialysis, Section 80 Home Dialysis Billing to the A/B MAC (A)
    • Chapter 17, Section 10 Payment Rules for Drugs and Biologicals, Section 20.5.8 Injections Furnished to ESRD Beneficiaries, Section 80.8 Reporting of Hematocrit and/or Hemoglobin Levels, Section 80.9 Required Modifiers for ESAs Administered to Non-ESRD Patients, Section 80.10 Hospitals Billing for Epoetin Alfa (EPO) and Darbepoetin Alfa (Aranesp) for Non-ESRD Patients, Section 80.11 Requirement for Providing Route of Administration Codes for Erythropoiesis Stimulating Agents (ESAs), Section 80.12 Claims Processing Rules for ESAs Administered to Cancer Patients for Anti-Anemia Therapy.
  • CMS IOM Publication 100-08, Medicare Program Integrity Manual,
    • Chapter 13, Section 13.5.4 Reasonable and Necessary Provision in an LCD

Social Security Act (Title XVIII) Standard References:

  • Title XVIII of the Social Security Act, Section 1862(a)(1)(A) states that no Medicare payment shall be made for items or services which are not reasonable and necessary for the diagnosis or treatment of illness or injury.
  • Title XVIII of the Social Security Act, Section 1842(u) states information related to hemoglobin & hematocrit must be included.
  • Title XVIII of the Social Security Act, Section 1881(b)(11)(B) is related to PPS of erythropoietin.
  • Title XVIII of the Social Security Act, Section 1881(b)(12)(H) related to no administrative or judicial review.


Sorry, you need to login or register to view additional sections of this Medicare policy.

--
*
All information on this web site is compiled directly from information obtained from the Center for Medicare and Medicaid Services (CMS) and from its Contractors.

CodeMap® has made every reasonable effort to ensure the accuracy of the information contained on this web site. However, the ultimate responsibility for correct coding and claims submission lies with the provider of services. CodeMap® makes no representation, warranty, or guarantee that this compilation of Medicare information is error-free or that the use of this information will result in Medicare coverage and subsequent payment of claims. Final coverage and payment of claims are subject to many factors exclusively controlled by CMS and its contractors.

No part of this web page or data displayed may be redistibuted or used without the express written consent of Wheaton Partners, LLC.

12/07/2022 11:54:33 3.225.221.130


CodeMap® is a Registered Trademark of Wheaton Partners, LLC.